Galderma celebrates diversity and inclusion with its first ever presence at NYC Pride

News provided by

Jun 23, 2022, 08:00 ET

Join Restylane^®, Dysport^® and Sculptra^® at PrideFest 2022

FORT WORTH, Texas, June 23, 2022 /PRNewswire/ -- Galderma announced today its upcoming participation in New York City's official LGBTQIA+ Pride (NYC Pride) event. The company's aesthetics portfolio, inclusive of the award-winning brands Restylane^®, Dysport^® (abobotulinumtoxinA) and Sculptra^®, is hosting in-person, interactive activations at PrideFest on Sunday, June 26^th.

"We are honored to be a part of NYC Pride this year," said Carrie Caulkins, Vice President, U.S. Aesthetics Marketing at Galderma. "There is power in defining your appearance on your own terms. Consumers, including those in the LGBTQIA+ patient population, are turning to aesthetics now more than ever to honor their identity. The best part about the Galderma Aesthetics portfolio is that you can express yourself naturally – every smile, laugh, frown, and expression in between is authentically you."

This month marks the official launch of Restylane's "XpresYourself" communications campaign, which gives a nod to Restylane's XpresHAn Technology™, a unique manufacturing process in four Restylane products* which allows them to maintain natural movement and expressions for natural-looking results.^1-3 The campaign complements the NYC Pride 2022 theme, "Unapologetically Us," which celebrates the community's resilience and determination to live out their truth with no apologies.

Galderma will be onsite providing information about Restylane, Dysport and Sculptra with special live performances throughout the day, a chance to win prizes, personalized consultations with top NYC aesthetic injectors and the opportunity to receive up to $200 off Galderma Aesthetics treatments through a special Galderma ASPIRE Rewards offer. In addition to in-person activations, Galderma will also kick off its dedicated XpresYourself influencer program with ongoing talent collaborations through the end of the year.

"Each day we strive to advance dermatology for every skin story," Caulkins said. "Galderma is excited for the opportunity to express its ongoing commitment to the LGBTQIA+ community and looks forward to celebrating Pride this month and beyond."

For those unable to join Galderma at NYC PrideFest, check out RestylaneUSA, DysportUSA and SculptraUSA on Instagram to follow all of the onsite action.

To learn more about Galderma's portfolio, visit www.galderma.com/us.

*Products formulated with XpresHAn Technology™ include Restylane^® Contour, Restylane^® Kysse, Restylane^® Defyne and Restylane^® Refyne.

Indication: Dysport is a prescription injection for temporary improvement in the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults less than 65 years of age.

Please read full Important Safety Information, including Distant Spread of Toxin Effect Boxed Warning, at the bottom of the page.

About Galderma
Galderma is the world's largest independent dermatology company, present in approximately 100 countries. Since our inception in 1981, we have been driven by a complete dedication to dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Aesthetics, Consumer Care and Prescription Medicine. Focused on the needs of consumers and patients, we work in partnership with healthcare professionals to ensure superior outcomes. Because we understand that the skin we're in shapes our life stories, we are advancing dermatology for every skin story. For more information: www.galderma.com/us.

About Galderma's RESTYLANE^® Product Portfolio
With over 50 million treatments worldwide⁴ and counting, the Restylane^® family of HA dermal fillers is a diverse and broad portfolio of dermal fillers in the U.S. These products help smooth facial wrinkles and folds, such as smile lines (Restylane^® L, Restylane^® Refyne, Restylane^® Defyne and Restylane^® Lyft with Lidocaine), augment and correct mild to moderate chin retrusion (Restylane^® Defyne), create fuller and more accentuated lips (Restylane^® Silk, Restylane^®-L and Restylane^® Kysse), add lift and volume to the cheeks and back of the hands (Restylane^® Lyft with Lidocaine), and augment cheeks and correct midface contour deficiencies (Restylane^® Contour). To learn more about the Restylane^® family of HA dermal fillers, visit www.RestylaneUSA.com.

About Galderma's collaboration with Ipsen
Dysport^® (abobotulinumtoxinA) is a prescription injection for temporary improvement in the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults less than 65 years of age. Dysport is also marketed as AZZALURE^® in the EU for the treatment of glabellar lines with more than 40 million treatments in the EU and U.S. combined and with approvals in 74 countries. To learn more about Dysport products, visit www.DysportUSA.com.

Dysport is manufactured by Ipsen, a global specialty-driven pharmaceutical company. Since 2009, Galderma and Ipsen have had a strategic partnership under which Galderma has promoted and distributed Ipsen's botulinum toxin type A products in aesthetic indications. The Ipsen-Galderma strategic partnership now covers China, the United States, the European Union, Australia, South Korea, Canada, Brazil, Argentina and certain other countries. Ipsen continues to promote Dysport within certain therapeutic indications in countries around the world. For more information on Ipsen, visit www.ipsen.com.

About SCULPTRA^®Sculptra^® works to help stimulate the skin's own collagen production and is indicated for use in people with healthy immune systems for the correction of shallow to deep nasolabial fold contour deficiencies and other facial wrinkles.^5,6

Sculptra is an injectable biostimulator containing microparticles of poly-l-lactic acid (PLLA) which helps gradually revitalize the skin's structural foundation, providing natural-looking, long-term results for up to 2 years^†.^5,7-8 Sculptra was first approved for aesthetic use in 2009 in the United States and is currently available in more than 40 countries globally. To learn more about Sculptra products, visit www.SculptraUSA.com

^†Clinical study ended at 96 weeks (2 years)

To earn exclusive rewards, bonuses and discounts on Galderma's aesthetic treatments, join the ASPIRE Galderma Rewards program. To learn more, visit www.aspirerewards.com.

Investor and media relations
Christian Marcoux, M.Sc.
Chief Communications Officer
[email protected]
+41 21 642 71 99

Media
Shannon Iwaniuk
Director of Communications
[email protected]

DYSPORT IMPORTANT SAFETY INFORMATION

Dysport^® (abobotulinumtoxinA) is a prescription injection for temporary improvement in the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults less than 65 years of age.

Important Safety Information

What is the most important information you should know about Dysport? Spread of Toxin Effects: In some cases, the effects of Dysport and all botulinum toxin products may affect areas of the body away from the injection site. Symptoms can happen hours to weeks after injection and may include swallowing and breathing problems, loss of strength and muscle weakness all over the body, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, or loss of bladder control. Swallowing and breathing problems can be life threatening and there have been reports of death. You are at the highest risk if these problems are pre‐existing before injection.

These effects could make it unsafe for you to drive a car, operate machinery, or do other dangerous activities.

Do not have Dysport treatment if you: are allergic to Dysport or any of its ingredients (see the end of the Medication Guide for a list of ingredients), are allergic to cow's milk protein, had an allergic reaction to any other botulinum toxin product, such as Myobloc^®, Botox^®, or Xeomin^®, have a skin infection at the planned injection site, under 18 years of age, or are pregnant or breastfeeding.

The dose of Dysport is not the same as the dose of any other botulinum toxin product and cannot be compared to the dose of any other product you may have used.

Tell your doctor about any swallowing or breathing difficulties and all your muscle or nerve conditions such as amyotrophic lateral sclerosis [ALS or Lou Gehrig's disease], myasthenia gravis, or Lambert‐Eaton syndrome, which may increase the risk of serious side effects including difficulty swallowing and difficulty breathing. Serious allergic reactions have occurred with the use of Dysport. Dry eye has also been reported.

Tell your doctor about all of your medical conditions, including if you have surgical changes to your face, very weak muscles in the treatment area, any abnormal facial change, injection site inflammation, droopy eyelids or sagging eyelid folds, deep facial scars, thick oily skin, wrinkles that can't be smoothed by spreading them apart, or if you are pregnant or breastfeeding or planning to become pregnant or breastfeed.

Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins and herbal and other natural products. Using Dysport with certain other medicines may cause serious side effects. Do not start any new medicines while taking Dysport without talking to your doctor first.

Especially tell your doctor if you: have received any other botulinum toxin product, such as Myobloc^® (rimabotulinumtoxinB), Botox^® (onabotulinumtoxinA), or Xeomin^® (incobotulinumtoxinA), in the last four months or any in the past (be sure your doctor knows exactly which product you received, have recently received an antibiotic by injection, take muscle relaxants, take an allergy or cold medicine, or take a sleep medicine.

Common Side Effects
The most common side effects are nose and throat irritation, headache, injection site pain, injection site skin reaction, upper respiratory tract infection, eyelid swelling, eyelid drooping, sinus inflammation, and nausea.

Ask your doctor if Dysport is right for you.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see Dysport Full Prescribing Information including Medication Guide at DysportUSA.com.

RESTYLANE IMPORTANT SAFETY INFORMATION

The Restylane family of products are indicated for patients over the age of 21, and includes Restylane^®, Restylane-L^®, Restylane^® Lyft with Lidocaine, Restylane^® Silk, Restylane^® Kysse, Restylane^® Refyne, Restylane^® Defyne, and Restylane^® Contour.

APPROVED USES

Restylane^® and Restylane-L^® are for mid-to-deep injection into the facial tissue for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds. Restylane^® and Restylane-L^® are also indicated for injection into the lips.

Restylane^® Lyft with Lidocaine is for deep implantation into the facial tissue for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds and for cheek augmentation and for the correction of age-related midface contour deficiencies. Restylane^® Lyft with Lidocaine is also indicated for injection into the dorsal hand to correct volume loss.

Restylane^® Silk is for lip augmentation and for correction of perioral wrinkles.

Restylane^® Kysse is for lip augmentation and for correction of upper perioral wrinkles.

Restylane^® Refyne is for mid-to-deep injection into the facial tissue for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds.

Restylane^® Defyne is for mid-to-deep injection into the facial tissue for the correction of moderate to severe deep facial wrinkles and folds, such as nasolabial folds. Restylane^® Defyne is also indicated for injection into the mid-to deep dermis (subcutaneous and/or supraperiosteal) for augmentation of the chin region to improve the chin profile in patients with mild to moderate chin retrusion.

Restylane^® Contour is for cheek augmentation and for the correction of midface contour deficiencies.

Do not use if you have severe allergies with a history of severe reactions (anaphylaxis), are allergic to lidocaine or gram-positive bacterial proteins used to make hyaluronic acid, prone to bleeding, or have a bleeding disorder. The safety of use while pregnant or breastfeeding has not been studied. Tell your doctor if you have a history of scarring or pigmentation disorders as these side effects can occur with hyaluronic acid fillers. Tell your doctor if you are planning other cosmetic treatments (i.e., lasers and chemical peels) as there is a possible risk of inflammation at the injection site.

Tell your doctor if you're taking medications that lower your body's immune response or affect bleeding, such as aspirin or warfarin, as these medications may increase the risk of bruising or bleeding at the gel injection site. Using these products on gel injection sites with skin sores, pimples, rashes, hives, cysts, or infections should be postponed until healing is complete.

The most common side effects are swelling, redness, pain, bruising, headache, tenderness, lump formation, itching at the injection site, and impaired hand function. Serious but rare side effects include delayed onset infections, recurrence of herpetic eruptions, and superficial necrosis at the injection site. The risk of unintentional injection into a blood vessel is small but can occur and could result in serious complications, which may be permanent including, vision abnormalities, blindness, stroke, temporary scabs, or permanent scarring of the skin. As with all skin injection procedures, there is a risk of infection.

To report a side effect with any Restylane^® product, please call Galderma Laboratories, L.P. at 1-855-425-8722.

To learn more about serious but rare side effects and full Important Safety Information, visit www.RestylaneUSA.com.

SCULPTRA IMPORTANT SAFETY INFORMATION

Indication: Sculptra^® (injectable poly-L-lactic acid) is indicated for use in people with healthy immune systems for the correction of shallow to deep nasolabial fold contour deficiencies and other facial wrinkles.

Sculptra should not be used by people that are allergic to any ingredient of the product or have a history of keloid formation or hypertrophic scarring. Safety has not been established in patients who are pregnant, lactating, breastfeeding, or under 18 years of age.

Sculptra has unique injection requirements and should only be used by a trained healthcare practitioner. Contour deficiencies should not be overcorrected because they are expected to gradually improve after treatment.

Sculptra should not be injected into the blood vessels as it may cause vascular occlusion, infarction or embolic phenomena. Use at the site of skin sores, cysts, pimples, rashes, hives or infection should be postponed until healing is complete. Sculptra should not be injected into the red area (vermillion) of the lip or in the peri-orbital area.

The most common side effects after initial treatment include injection site swelling, tenderness, redness, pain, bruising, bleeding, itching and lumps. Other side effects may include small lumps under the skin that are sometimes noticeable when pressing on the treated area. Larger lumps, some with delayed onset with or without inflammation or skin discoloration, have also been reported.

Sculptra is available only through a licensed practitioner. Complete Instructions for Use are available at www.SculptraUSA.com/IFU.

References:

Philipp-Dormston WG, Schuster B, PoddaM. Perceived naturalness of facial expression after hyaluronic acid filler injection in nasolabial folds and lower face. J Cosmet Dermatol. 2020;19:1600-16064.
Öhrlund Å. Evaluation of rheometry amplitude sweep cross-over point as an index of flexibility for HA fillers. JCDSA.2018;8:47-54.
Data on file. MA-34483 Study Report. Fort Worth, TX: Galderma Laboratories, L.P., 2021.
Data on file. MA-39680. Fort Worth, TX: Galderma Laboratories, L.P., 2019.
Sculptra. Instructions for Use. Galderma Laboratories, L.P., 2021.
Goldberg D, Guana A, Volk A, Daro-Kaftan E. Single-arm study for the characterization of human tissue response to injectable poly-L-lactic acid. Dermatol Surg. 2013;39(6):915-922.
Stein P, Vitavska O, Kind P, Hoppe W, Wieczorek H, Schürer NY. The biological basis for poly-L-lactic acid-induced augmentation. J Dermatol Sci. 2015;78:26-33.
Data on file. 43USSA1705ext clinical study report. Fort Worth, TX: Galderma Laboratories, L.P. 2021.